Promoting Transparency in Pharmaceutical Industry-Sponsored Research
Promoting Transparency in Pharmaceutical Industry-Sponsored Research
复制标题
DOI：
10.2105/ajph.2011.300187
复制
发表时间：
2012-01-01
影响因子：
12.7
通讯作者：
Krumholz, Harlan M.
中科院分区：
文献类型：
--
作者：
Ross, Joseph S.;Gross, Cary P.;Krumholz, Harlan M.
强有力的循证实践要求提供客观、不偏不倚的研究来为个人临床决策、系统评价、荟萃分析和专家指南建议提供信息。行业使用种子试验、出版计划、消息传递、代写以及试验结果的选择性发布和报告来扭曲医学文献，并通过模糊与患者和医生相关的信息来破坏临床试验研究。通过改善和扩大研究人员贡献和资金的披露、全面公开的试验注册和临床试验数据分析的独立分析来促进临床试验研究过程的透明度的政策，可能会通过改善行业和研究人员之间的问责来解决这些颠覆性的做法。将营销对临床试验研究的影响降至最低，并加强科学性，将保护医学文献的完整性和公众的健康。(我是J公共卫生。2012年：72胜80负。DOI：10.2105/AJPH.2011.300187)
Strong, evidence-based practice requires that objective, unbiased research be available to inform individual clinical decisions, systematic reviews, meta-analyses, and expert guideline recommendations.Industry has used seeding trials, publication planning, messaging, ghostwriting, and selective publication and reporting of trial outcomes to distort the medical literature and undermine clinical trial research by obscuring information relevant to patients and physicians.Policies that promote transparency in the clinical trial research process, through improved and expanded disclosure of investigator contributions and funding, comprehensive publicly available trial registration, and independent analysis of clinical trial data analysis may address these subversive practices by improving accountability among industry and investigators. Minimizing marketing's impact on clinical trial research and strengthening the science will protect medical literature's integrity and the public's health. (Am J Public Health. 2012:72-80. doi :10.2105/AJPH.2011.300187)